Lothar Leimer

1.2k total citations
14 papers, 828 citations indexed

About

Lothar Leimer is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Genetics. According to data from OpenAlex, Lothar Leimer has authored 14 papers receiving a total of 828 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Public Health, Environmental and Occupational Health, 8 papers in Hematology and 5 papers in Genetics. Recurrent topics in Lothar Leimer's work include Acute Lymphoblastic Leukemia research (9 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Lothar Leimer is often cited by papers focused on Acute Lymphoblastic Leukemia research (9 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Lothar Leimer collaborates with scholars based in Germany, Austria and Italy. Lothar Leimer's co-authors include Markus Schaich, Dieter Hoelzer, Knut Wendelin, Nicola Gökbuget, Albrecht Reichle, Hubert Serve, Reingard Stuhlmann, Joachim Beck, H. Diedrich and Matthias Stelljes and has published in prestigious journals such as The Lancet, Blood and Leukemia.

In The Last Decade

Lothar Leimer

14 papers receiving 812 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lothar Leimer Germany 10 490 430 264 144 135 14 828
Roswitha Dickerhoff Germany 12 245 0.5× 80 0.2× 114 0.4× 28 0.2× 62 0.5× 37 556
PI Warkentin United States 15 589 1.2× 175 0.4× 201 0.8× 18 0.1× 56 0.4× 28 718
Jean Pierre Jouet France 13 731 1.5× 146 0.3× 164 0.6× 17 0.1× 54 0.4× 24 904
Guru Subramanian Guru Murthy United States 13 338 0.7× 114 0.3× 160 0.6× 13 0.1× 45 0.3× 81 520
V Altomonte United States 13 562 1.1× 73 0.2× 179 0.7× 6 0.0× 56 0.4× 15 781
WY Au China 14 312 0.6× 46 0.1× 102 0.4× 13 0.1× 20 0.1× 47 549
D. Kingreen Germany 15 169 0.3× 48 0.1× 184 0.7× 16 0.1× 19 0.1× 27 642
G. А. Novichkova Russia 11 238 0.5× 90 0.2× 87 0.3× 10 0.1× 27 0.2× 147 457
Josefine Palle Sweden 17 659 1.3× 363 0.8× 216 0.8× 3 0.0× 113 0.8× 58 912
J Bruton United States 6 836 1.7× 218 0.5× 258 1.0× 2 0.0× 47 0.3× 8 956

Countries citing papers authored by Lothar Leimer

Since Specialization
Citations

This map shows the geographic impact of Lothar Leimer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lothar Leimer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lothar Leimer more than expected).

Fields of papers citing papers by Lothar Leimer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lothar Leimer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lothar Leimer. The network helps show where Lothar Leimer may publish in the future.

Co-authorship network of co-authors of Lothar Leimer

This figure shows the co-authorship network connecting the top 25 collaborators of Lothar Leimer. A scholar is included among the top collaborators of Lothar Leimer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lothar Leimer. Lothar Leimer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Wandt, Hannes, Kerstin Schaefer‐Eckart, Knut Wendelin, et al.. (2012). Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet. 380(9850). 1309–1316. 210 indexed citations
2.
3.
Gökbuget, Nicola, Joachim Beck, H. Diedrich, et al.. (2012). Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 120(10). 2032–2041. 321 indexed citations
4.
Gökbuget, Nicola, Renato Bassan, Hans Guenter Derigs, et al.. (2010). Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. Haematologica. 96(2). 238–244. 44 indexed citations
5.
6.
Fuchs, Robyn K., Lothar Leimer, Guido Koch, & M. Westerhausen. (2008). Klinische Erfahrungen mit bakteriell kontaminierten Port-A-Cath-Systemen bei Tumorpatienten. DMW - Deutsche Medizinische Wochenschrift. 112(42). 1615–1618. 1 indexed citations
7.
8.
Goekbuget, Nicola, Anja Baumann, Joachim Beck, et al.. (2008). PEG-Asparaginase in Adult Acute Lymphoblastic Leukemia (ALL): Efficacy and Feasibility Analysis with Increasing Dose Levels. Blood. 112(11). 302–302. 20 indexed citations
9.
10.
11.
Waßmann, Barbara, Urban Scheuring, Roman Pfeifer, et al.. (2003). Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia. 17(10). 1919–1924. 27 indexed citations
12.
Waßmann, Barbara, Roman Pfeifer, Urban Scheuring, et al.. (2003). Early prediction of response in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. Blood. 103(4). 1495–1498. 39 indexed citations
13.
Pfeifer, Roman, Barbara Waßmann, Wolf‐Karsten Hofmann, et al.. (2003). Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.. PubMed. 9(13). 4674–81. 77 indexed citations
14.
Rummel, Mathias, Kai Uwe Chow, Elke Jäger, et al.. (1999). Intermittent 2-Hour-Infusion of Cladribine as First-Line Therapy or in First Relapse of Progressive Advanced Low-Grade and Mantle Cell Lymphomas. Leukemia & lymphoma. 35(1-2). 129–138. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roswitha Dickerhoff Breakdown of academic impact, for papers by PI Warkentin Breakdown of academic impact, for papers by Jean Pierre Jouet Breakdown of academic impact, for papers by Guru Subramanian Guru Murthy Breakdown of academic impact, for papers by V Altomonte Breakdown of academic impact, for papers by WY Au Breakdown of academic impact, for papers by D. Kingreen Breakdown of academic impact, for papers by G. А. Novichkova Breakdown of academic impact, for papers by Josefine Palle Breakdown of academic impact, for papers by J Bruton
Rankless by CCL
2026